{"id":85141,"date":"2026-04-27T16:57:02","date_gmt":"2026-04-27T16:57:02","guid":{"rendered":"https:\/\/diyhaven858.wasmer.app\/index.php\/pharmalittle-were-reading-about-a-lilly-deal-an-intellia-crispr-rare-disease-treatment-and-more\/"},"modified":"2026-04-27T16:57:02","modified_gmt":"2026-04-27T16:57:02","slug":"pharmalittle-were-reading-about-a-lilly-deal-an-intellia-crispr-rare-disease-treatment-and-more","status":"publish","type":"post","link":"https:\/\/diyhaven858.wasmer.app\/index.php\/pharmalittle-were-reading-about-a-lilly-deal-an-intellia-crispr-rare-disease-treatment-and-more\/","title":{"rendered":"Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and more"},"content":{"rendered":"


\n<\/p>\n

\n

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on a cuppa stimulation. Our choice today is ginger honey. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today and, of course, do keep in touch. \u2026<\/p>\n

Intellia Therapeutics disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with a rare genetic disorder in a Phase 3 trial, setting up a potential approval<\/strong>, STAT tells us. The therapy, known as lonvo-z, would be the second approved CRISPR-based medicine, after Vertex Pharmaceutical\u2019s sickle cell treatment Casgevy. Intellia has already initiated a rolling submission with the agency. This would be the first in vivo treatment, meaning it edits patient DNA directly in the body.\u00a0The question for Intellia and for the field will be how attractive the one-and-done approach will be to patients and doctors. Hereditary angioedema, or HAE, which affects around 20,000 patients in the U.S. and Europe, has seen an influx of new treatments over the last few years.\u00a0<\/p>\n

Sun Pharmaceutical agreed to acquire Organon in a deal valued at $11.75 billion, putting the Indian drugmaker on track to become one of the top three global players in women\u2019s health<\/strong>, The Wall Street Journal notes. Sun, which specializes in generics and is one of the biggest pharma names in India by market cap, will fund the deal through a combination of internal cash resources and financing from banks. Organon, which was formed through a spinoff from Merck, has a portfolio of more than 70 products across women\u2019s health and general medicines, including biosimilars, commercialized across 140 countries. Its 2025 revenue was $6.2 billion. The acquisition will help lift Sun into the top 25 global pharmaceutical companies, with a revenue of $12.4 billion.<\/p>\n

\n
\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/p>\n<\/p><\/div>\n

\t\t\t\"STAT+\"\/<\/p>\n

\n\t\t\t\t<\/p>\n

\t\t\t\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t<\/span><\/p>\n

This article is exclusive to STAT+ subscribers<\/h2>\n

Unlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/h3>\n

Already have an account? Log in<\/p>\n

\n
\n\t\t\t\t\t\t